

Apo-ONE® Homogeneous Caspase-3/7 Assay (Promega®) automated on the epMotion® 5075t*

Introduction

Cell-based assays (CBA), measuring complex cellular mechanisms, are widely used in research and pharmaceutical industry for drug identification or characterization. Apoptosis assay, as Cell Viability and Cytotoxicity assays, is a CBA presenting high relevance on the market. The Apo-ONE Homogeneous Caspase-3/7 assay from Promega is a fluorometric method measuring the activities of caspase-3 and caspase-7 playing a key effector role in apoptosis in mammalian cells. This assay can easily be configured for use on the epMotion 5075t. Working with cells implies the necessity to work under clean conditions which is provided by the CleanCap option of the epMotion 5075t. This method could be used for adherent or suspension culture cells. The use of the epMotion 5075t allows handling of multiple 96-well plates in parallel.

This protocol describes the methods used to evaluate a dose response curve of staurosporine toxic compound on adherent Jurkat cells after 5-hour incubation. The workflow is divided into three different steps. On the first day, the cells are seeded in 96-well plates. On the second day, the toxic compound solution is prepared and added to the cells present in the 96-well plate then the CBA assay itself is performed. The cell seeding, the compound dilutions, the compound addition and the assays are performed on the epMotion 5075t. These three steps correspond to three methods on the epMotion. The run time for the entire procedure is 42 minutes for three 96-well plates processed in parallel.

In accordance to the experimental design of the user (Cell amount and type, compound concentration, incubation time, plate design, and plate number), the procedure needs to be adapted. An optimization of the liquid class parameters might be required if another compound is tested.

Materials and Methods

This protocol is programmed to process three 96-well plates in parallel. The complete workflow is divided into three epMotion methods. For the two first methods, the epMotion surfaces and tools are cleaned using a disinfection solution. Both UV-lights and air filters are started 15 minutes before using the system, whereas UV stopped automatically after this time span. At the end of each method, a user intervention is requested to handle the plates to downstream steps (incubation, reading).

Method 1

Before starting the method 1, a solution of Jurkat cells cultivated in RPMI 1640 Medium supplemented with 10 % FBS, 1 % Penicillin-Streptomycin and 2 nM of L-glutamine at a concentration of 10,000 cells per 90 µL is prepared in a sterile tube and transferred in a sterile autoclaved epMotion reservoir of 100 mL on the epMotion. Culture medium (RPMI 1640 Medium supplemented with 2 mM L-glutamine, 10 % FBS and 1 % Penicillin-Streptomycin) without cells, used as blank, is transferred in a sterile epMotion reservoir of 30 mL on the epMotion.

Method 1

Before starting the method 1, a solution of Jurkat cells cultivated in RPMI 1640 Medium supplemented with 10 % FBS, 1 % Penicillin-Streptomycin and 2 nM of L-glutamine at a concentration of 10,000 cells per 90 μ L is prepared in a sterile tube and transferred in a sterile autoclaved epMotion reservoir of 100 mL on the epMotion. Culture medium (RPMI 1640 Medium supplemented with 2 mM L-glutamine, 10 % FBS and 1 % Penicillin-Streptomycin) without cells, used as blank, is transferred in a sterile epMotion reservoir of 30 mL on the epMotion.

These steps need to be performed under sterile cell culture conditions.

The method 1 comprises the dispensing of 90 μ L of cells per well in columns 1 to 11 in three 96-well microplates and 90 μ L of culture medium without cells in column 12 in these three plates. At the end of the program, the lid is manually replaced on the plates and the plates are placed into the CO₂ incubator at 37 °C for 24 hours.

Method 1



Figure 1: Reservoir rack layout for method 1

Method 2

The method 2 includes 2 parts separated by a "Stop – User intervention" command.

In order to avoid that the cells stay on the worktable at room temperature during the first part of the method, the 96-well plates seeded with cells are not positioned on the worktable for the first part of the method. Due to the plates' absence, during the check of the labware position, a message will appear on the computer screen informing that nothing could be found at the position of the 96-well plates (B3, B4 and B5). The procedure can be carried on by choosing the "ignore" selection. The "Stop command" at the end of the first part allows the user to place the 96-well plates on the worktable for the second part of this method.

The first part consists in the preparation of staurosporine (STS) concentration curve solutions in a Deepwell plate from a STS stock solution at 10.7 mM. In order to generate a concentration curve with the same amount of vehicle solution into each well, the dilution curve is performed using two different dilutions steps. The first dilution is performed into DMSO 99.9 % vehicle solution and the second dilution into culture medium without FBS 10x concentrate. Culture medium without STS and DMSO is used as negative control

to measure the effect of DMSO on cells and is added into column 5 of the Deepwell Plate. At the end of this first part, the 96-well plates seeded with the cells are placed on the worktable.

The second part includes the dispensing of the STS concentration curve solutions from the Deepwell plate to the 96-well plates. 10 µL is added per well. In a first time, 10 µL of culture medium without STS and DMSO was added in column 12 and 11 of the plates. Secondly, 10 µL of STS solution is added in the plates.

All STS solutions are dispensed in one plate first and the operations are then repeated for the second and third plates. The final concentration of the vehicle solution is composed of 0.93 % DMSO. The plates are transferred on the Thermo-Mixer® and mixed at 500 rpm for 30 sec. At the end of the method, the lid is replaced on the plates manually and the plates are placed back in the CO₂ incubator at 37 °C for 5 hours.

These steps need to be performed under sterile cell culture conditions.

Method 2




Figure 2: Reservoir rack layout for method 2

96-well plate layout

	1	2	3	4	5	6	7	8	9	10	11	12
A	0 µM	0 µM	0 µM	0 µM	0 µM	500 nM	500 nM	500 nM	500 nM	500 nM	Negative Control	Blank
B	3 nM	3 nM	3 nM	3 nM	3 nM	1 µM	1 µM	1 µM	1 µM	1 µM		
C	5 nM	5 nM	5 nM	5 nM	5 nM	3 µM	3 µM	3 µM	3 µM	3 µM		
D	10 nM	10 nM	10 nM	10 nM	10 nM	5 µM	5 µM	5 µM	5 µM	5 µM		
E	30 nM	30 nM	30 nM	30 nM	30 nM	10 µM	10 µM	10 µM	10 µM	10 µM		
F	50 nM	50 nM	50 nM	50 nM	50 nM	15 µM	15 µM	15 µM	15 µM	15 µM		
G	100 nM	100 nM	100 nM	100 nM	100 nM	20 µM	20 µM	20 µM	20 µM	20 µM		
H	300 nM	300 nM	300 nM	300 nM	300 nM	100 µM	100 µM	100 µM	100 µM	100 µM		

Method 3

After 5 hours of incubation, the plates are removed from the CO₂ incubator. This method includes the dispensing of 100 µL freshly prepared Apo-ONE Caspase-3/7 reagent to each well of three 96-well plates. The solution is firstly dispensed into the blank and negative controls. The plates are transferred on the ThermoMixer and mixed at 500 rpm for 30 sec. At the end of this method, the lid is replaced on the plates manually and the plates are incubated for 1 hour at room temperature protected from light.

Method 3




Figure 3: Reservoir rack layout for method 3

Results

At the end of the complete process, the plate reading of the 96-well plates is performed. After quick shake of the plates for 10 sec, the fluorescence is measured in each well using an excitation wavelength of 485 nm and emission wavelength of 535 nm. The same gain was used to measure the fluorescence between plate replicates.

The toxic effect of staurosporine on Jurkat cells using this short protocol is illustrated on figure 4. A fluorescence increase is observed due to the higher caspase-3/7 enzymatic activity present for high staurosporine concentration.




Figure 4: Caspase-3/7 measurement using Apo-ONE Homogeneous Caspase-3/7 Assay. Staurosporine dose curve response on Jurkat cells after 5-hour incubation was performed. Five replicates per concentration were performed and three plates were processed in parallel on the epMotion.

Ordering information

Description	Order no. international	Order no. North America
epMotion® 5075t	5075 000 042	5075000042
epMotion® 5075t CleanCap upgrade set	5075 001 888	5075001888
Gripper	5282 000 018	960002270
TS50 pipetting tool	5280 000 010	960001010
TM50-8 pipetting tool	5280 000 215	960001044
TM1000-8 pipetting tool	5280 000 258	960001061
ReservoirRack for epMotion®	5075 754 002	960002148
CellXpert® C170i (Cell Culture Incubator)	see online	see online
epT.I.P.S.® Motion 50 µL Filter	0030 015 215	0030015215
epT.I.P.S.® Motion 1000 µL Filter	0030 015 258	0030015258
epMotion® Reservoir	0030 126 505	960051009
30 mL	0030 126 513	960051017
100 mL		
Reservoir Rack Module TC, for use in epMotion® Reservoir Racks, temperable, 4 x Safe-Lock tubes 0.5/1.5/2.0 mL	5075 799 081	960002620
Eppendorf Safe-Lock Tubes, 1.5 mL	0030 120 086	022363204
Eppendorf Deepwell Plate 96/1000 µL	0030 502 205	951032701
Waste bag	5075 752 034	5075752034

Your local distributor: www.eppendorf.com/contact

Eppendorf SE · 22331 Hamburg · Germany

eppendorf@eppendorf.com · www.eppendorf.com

www.eppendorf.com

Sigma-Aldrich® is a registered trademark of Sigma-Aldrich Co., LLC Lim., USA. Promega® and Apo-ONE® are registered trademarks of Promega Corporation, USA. Umonium38® is a registered trademark of Etienne Huckert, Belgium. Life Technologies® is a registered trademark of Thermo Fisher Scientific, Inc., USA. Eppendorf®, the Eppendorf brand design, epMotion®, epT.I.P.S.® and ThermoMixer® are registered trademarks of Eppendorf SE, Germany. Galaxy® is a registered trademark of Eppendorf, Inc., USA. U.S. Design Patents are listed on www.eppendorf.com/ip. All rights reserved, including graphics and images. Copyright © 2024 by Eppendorf SE, Germany.

Methods are intended for molecular research applications. They are not intended, verified or validated for use in the diagnosis of disease or other human health conditions.

*Developed on a predecessor model, but thanks to the migration feature, this method can easily be transferred to the newest generation of epMotion®.